HBeAg-positive hepatitis delta: Virological patterns and clinical long-term outcome

Liver International

Volumn 32, Issue 9, 2012, Pages 1415-1425

  Heidrich, Benjamin ^a   C Serrano, Beatriz ^a   Idilman, Ramazan ^c   Kabaçam, Gökhan ^c   Bremer, Birgit ^a   Raupach, Regina ^a   Önder, Fatih O ^c   Deterding, Katja ^a   Zacher, Behrend J ^a   Taranta, Andrzej ^a   Bozkaya, Hakan ^c   Zachou, Kalliopi ^a,d   Tillmann, Hans L ^a,b   Bozdayi, Abdurrahman M ^c   Manns, Michael P ^a   Yurdaydin, Cihan ^c   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c ANKARA UNIVERSITY   (Turkey)

^d UNIVERSITY OF THESSALY   (Greece)

Author keywords

HBeAg positive; HBV; HDV; Hepatitis delta

Indexed keywords

ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DELTA AGENT HEPATITIS; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; OUTCOME ASSESSMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; GERMANY; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84865718431     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02831.x     Document Type: Article

References (47)

1. Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136: 1629-38.
2. Niro GA, Smedile A, Ippolito AM, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol 2010; 53: 834-40.
3. Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18: 997-1003.
4. Hadziyannis S. Hepatitis delta: an overview. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, eds. Viral Hepatitis and Liver Disease. Turin: Edizioni Minerva Medica, 1997; 283-9.
5. Mederacke I, Bremer B, Heidrich B, et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010; 48: 2022-9.
6. Farci P. Delta hepatitis: an update. J Hepatol 2003; 39(Suppl. 1): S212-9.
7. Ponzetto A, Forzani B, Parravicini PP, et al. Epidemiology of hepatitis delta virus (HDV) infection. Eur J Epidemiol 1985; 1: 257-63.
8. Cross TJ, Rizzi P, Horner M, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol 2008; 80: 277-82.
9. Kucirka LM, Farzadegan H, Feld JJ, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis 2010; 202: 845-52.
10. Heidrich B, Deterding K, Tillmann HL, et al. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat 2009; 16: 883-94.
11. Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34: 404-10.
12. Pollicino T, Raffa G, Santantonio T, et al. Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol 2011; 85: 432-9.
13. Saracco G, Rosina F, Brunetto MR, et al. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol 1987; 5: 274-81.
14. Sagnelli E, Felaco FM, Rapicetta M, et al. Interaction between HDV and HBV infection in HBsAg-chronic carriers. Infection 1991; 19: 155-8.
15. Williams V, Brichler S, Radjef N, et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol 2009; 90: 2759-67.
16. Kiesslich D, Crispim MA, Santos C, et al. Influence of hepatitis B virus (HBV) genotype on the clinical course of disease in patients coinfected with HBV and hepatitis delta virus. J Infect Dis 2009; 199: 1608-11.
17. Seetlani NK, Abbas Z, Raza S, Yakoob J, Jafris W. Prevalence of hepatitis D in HBsAg positive patients visiting liver clinics. J Pak Med Assoc 2009; 59: 434-7.
18. Sagnelli E, Stroffolini T, Mele A, Imparato M, Almasio PL. Chronic hepatitis B in Italy: new features of an old disease-approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection. Clin Infect Dis 2008; 46: 110-3.
19. Gu X, Li Q, Wang Y. Clinical characteristics of the patients with hepatitis B combining hepatitis D infection. Zhonghua Gan Zang Bing Za Zhi 2001; 9: 34-6.
20. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52.
21. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
22. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
23. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-52.
24. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
25. Ni YH, Chang MH, Chen PJ, et al. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 2007; 132: 2340-5.
26. Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006; 43: 556-62.
27. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-22.
28. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 829-34.
29. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-31.
30. Wursthorn K, Jaroszewicz J, Zacher BJ, et al. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 2011; 50: 292-6.
31. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24.
32. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986; 90: 1268-73.
33. Maruyama T, Iino S, Koike K, Yasuda K, Milich DR. Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 1993; 105: 1141-51.
34. Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol 2010; 52: 658-64.
35. Negro F, Bergmann KF, Baroudy BM, et al. Chronic hepatitis D virus (HDV) infection in hepatitis B virus carrier chimpanzees experimentally superinfected with HDV. J Infect Dis 1988; 158: 151-9.
36. Sakugawa H, Ohwan T, Yamashiro A, et al. Natural seroconversion from hepatitis Be antigen to antibody among hepatitis B virus carriers in Okinawa Islands. J Med Virol 1991; 34: 122-6.
37. Zacharakis GH, Koskinas J, Kotsiou S, et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol 2005; 77: 173-9.
38. Chang MH. Natural history of hepatitis B virus infection in children. J Gastroenterol Hepatol 2000; 15(Suppl.): E16-9.
39. Lindh G, Weiland O, Svedmyr A, Glaumann H, Hansson BG. Long-term follow-up of 60 patients with chronic hepatitis B. I. Seroconversion in the hepatitis B e-system, frequency of delta infection and histological outcome. Liver 1986; 6: 7-12.
40. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-13.
41. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378: 73-85.
42. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40.
43. European Association for The Study of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
44. Yurdaydin C, Bozkaya H, Heidrich B, et al. Treatment of HBeAg-positive chronic delta hepatitis with nucleos(t)ide analogs. Hepatology 2008; 48: 722.
45. Lau DT, Doo E, Park Y, et al. Lamivudine for chronic delta hepatitis. Hepatology 1999; 30: 546-9.
46. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 2010; 17: 749-56.
47. Sheldon J, Ramos B, Toro C, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther 2008; 13: 97-102.